SecSonar.com

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Regeneron Pharmaceuticals, Inc. (REGN) is a Biotechnology company based in US with a market capitalization of $63.5B. Revenue grew 1.0% year-over-year and the company generated $4.1B in free cash flow. This page tracks REGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 15.16K employees · IPO Apr 2, 1991

Valuation

Valuation & price

$714.89 · as of May 13, 2026 · -12.0% vs 52w high

17.2

P/E ratio

Latest-FY diluted EPS

2.03

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$803$671$538Jul 25Dec 25Jul 26Jul 7, 25$538.11Jul 9, 25$552.58Jul 11, 25$567.74Jul 15, 25$547.96Jul 17, 25$550.00Jul 21, 25$545.53Jul 23, 25$572.39Jul 25, 25$563.10Jul 29, 25$558.15Jul 31, 25$545.46Aug 4, 25$571.54Aug 6, 25$555.13Aug 11, 25$545.94Aug 13, 25$561.55Aug 15, 25$580.41Aug 19, 25$571.78Aug 21, 25$598.16Aug 25, 25$572.38Aug 27, 25$586.96Aug 29, 25$580.70Sep 3, 25$563.80Sep 5, 25$573.38Sep 9, 25$556.53Sep 11, 25$568.20Sep 16, 25$575.06Sep 18, 25$598.71Sep 22, 25$595.68Sep 24, 25$576.98Sep 26, 25$563.90Sep 30, 25$562.27Oct 2, 25$600.00Oct 6, 25$585.48Oct 8, 25$563.86Oct 10, 25$564.63Oct 14, 25$572.60Oct 16, 25$569.17Oct 21, 25$579.34Oct 23, 25$575.69Oct 27, 25$585.31Oct 29, 25$652.91Oct 31, 25$651.80Nov 4, 25$628.00Nov 6, 25$646.87Nov 10, 25$654.74Nov 12, 25$681.72Nov 14, 25$693.50Nov 18, 25$725.34Nov 20, 25$737.00Nov 25, 25$787.32Nov 28, 25$780.19Dec 2, 25$742.00Dec 4, 25$722.80Dec 8, 25$703.26Dec 10, 25$726.21Dec 12, 25$741.29Dec 16, 25$746.36Dec 18, 25$748.71Dec 22, 25$779.36Dec 24, 25$783.71Dec 29, 25$780.50Jan 2, 26$776.31Jan 6, 26$776.54Jan 8, 26$801.01Jan 12, 26$768.00Jan 14, 26$754.14Jan 16, 26$733.04Jan 21, 26$749.33Jan 23, 26$753.55Jan 27, 26$771.25Jan 29, 26$749.44Feb 2, 26$755.02Feb 4, 26$775.06Feb 9, 26$780.28Feb 11, 26$778.97Feb 13, 26$803.17Feb 18, 26$792.16Feb 20, 26$779.67Feb 24, 26$772.19Feb 26, 26$770.79Mar 2, 26$790.81Mar 4, 26$787.50Mar 6, 26$759.86Mar 10, 26$772.03Mar 12, 26$746.61Mar 17, 26$759.05Mar 19, 26$737.45Mar 23, 26$736.53Mar 25, 26$749.47Mar 27, 26$737.71Mar 31, 26$772.64Apr 2, 26$761.85Apr 7, 26$760.27Apr 9, 26$767.85Apr 13, 26$746.46Apr 15, 26$753.93Apr 17, 26$750.57Apr 22, 26$746.58Apr 24, 26$751.57Apr 28, 26$731.77Apr 30, 26$707.06May 4, 26$709.21May 6, 26$721.05May 8, 26$714.89May 12, 26$723.41May 14, 26$712.87May 18, 26$629.68May 20, 26$649.76May 22, 26$638.88May 28, 26$621.52Jun 1, 26$600.66Jun 3, 26$618.95Jun 5, 26$635.45Jun 9, 26$616.18Jun 11, 26$611.48Jun 15, 26$614.98Jun 17, 26$607.93Jun 22, 26$612.50Jun 24, 26$623.43Jun 26, 26$632.90Jul 2, 26$654.27
$538.1152-week range$812.27
Loading valuation history…

Fundamentals

Key fundamentals

$63.5B

Market cap

1.0%

Revenue growth (YoY)

85.3%

Gross margin

$4.1B

Free cash flow (USD)

-$5.9B

Net debt

Net cash position

-3.1%

Share dilution

3/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$4.9BFY 2017$5.9BFY 2018$6.7BFY 2019$6.6BFY 2020$8.5BFY 2021$16.1BFY 2022$12.2BFY 2023$13.1BFY 2024$14.2BFY 2025$14.3B
$4.9B$14.3B

Free cash flow by year

2016 → 2025

FY 2016$974.0MFY 2017$1.0BFY 2018$1.8BFY 2019$2.0BFY 2020$2.0BFY 2021$6.5BFY 2022$4.4BFY 2023$3.7BFY 2024$3.7BFY 2025$4.1B
$974M$4.1B

Gross margin by year

2021 → 2025

FY 202183.0%FY 202286.0%FY 202382.9%FY 202486.1%FY 202585.3%
83.0%85.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 29, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 17, 2026Filing
  • Insider sellInsider Sell $71K · 10b5-1 PlanRYAN ARTHUR F · Director · $70.5KMay 4, 2026Filing
  • 8-K eventEarnings ReleaseApr 29, 2026Filing
  • Quarterly report10-Q FiledApr 29, 2026Filing
  • 8-K eventFinancial Results UpdateApr 8, 2026Filing
  • Insider sellInsider Sell $78K · 10b5-1 PlanRYAN ARTHUR F · Director · $77.7KApr 3, 2026Filing

Questions

Frequently asked questions

What is Regeneron Pharmaceuticals, Inc.'s market cap?

Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalization of $63.5B.

What is REGN's P/E ratio?

REGN trades at a price-to-earnings ratio of 17.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is REGN's price-to-book (P/B) ratio?

REGN trades at 2.03 times book value per share.

Are insiders buying REGN stock?

SEC Form 4 filings show no open-market insider buys at Regeneron Pharmaceuticals, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

ARGX

argenx SE

$51.7B

ALNY

Alnylam Pharmaceuticals, Inc.

$40.3B

RVMD

Revolution Medicines, Inc.

$33.3B

RPRX

Royalty Pharma plc

$23.6B

UTHR

United Therapeutics Corporation

$23.4B

INSM

Insmed Incorporated

$23.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.